Your Yourlocation: Home > Clinical efficacy of combined therapy with cortisone and tiotropium bromide(136310-93-5) in the treatment of stable moderate to severe COPD

OBJECTIVE: To investigate the clinical efficacy and safety of long-range home oxygen therapy combined with inhalation of sulbide and tiotropium bromide(136310-93-5) in stable moderate to severe COPD.

Methods: Forty-two patients with COPD were randomly divided into treatment group(n = 62) and control group(n = 60). Both groups were treated with lung function, 6MWT, clinical effective rate before treatment and 12 weeks and 24 weeks after treatment, acute exacerbations of hospitalization, adverse drug reactions. The treatment group in the family oxygen therapy oxygen 1 ~ 2Umin, more than 15h daily, while inhaled sulinda (50 bucket g, 250 bucket g) /times, sooner or later the 1 times. Tiotropium bromide(136310-93-5) 18 g /s, once per night. Control group without family oxygen therapy, only tiotropium inhalation 18 g /times, once a night.

Results: The pulmonary function index(FEVl, FEVl%, FEVI/ FVC) of the treatment group at 12 weeks and 24 weeks after treatment was significantly better than that of the control group (P <0.05) at 12 weeks and 24 weeks after treatment. The treatment group(54 ± 16) m, (518 ± 18) m, which was significantly higher than that of the control group (380 ± 20) m, (402 ± 17) m (P <0.05). The total score of SGRQ and CAT (1.22 ± 0.20) times /24 weeks, the difference between the two groups was significant.There were significant differences between the two groups(0.12 ± 0.06) and control group(0.22 ± 0.04).

Conclusion: Long-term home oxygen therapy combined with inhalation of sulindole, tiotropium bromide(136310-93-5) in patients with moderate to severe COPD, improved lung function, improved quality of life, reduced hospitalization, worthy of further clinical promotion.

Address: TEL:0531-82375879 Tiotropium Bromide
© Copyright(C)2014 JINAN DEXINJIA BIO & TECH CO., LTD All Rights Reserved